Compare GEL & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GEL | RAPP |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | 84 |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1996 | 2024 |
| Metric | GEL | RAPP |
|---|---|---|
| Price | $16.38 | $34.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $19.50 | ★ $48.50 |
| AVG Volume (30 Days) | 278.9K | ★ 292.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,912,770,000.00 | N/A |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $14.55 | $7.73 |
| 52 Week High | $18.64 | $42.27 |
| Indicator | GEL | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 45.42 |
| Support Level | $16.28 | $25.48 |
| Resistance Level | $16.42 | $41.33 |
| Average True Range (ATR) | 0.47 | 2.50 |
| MACD | 0.00 | -0.38 |
| Stochastic Oscillator | 47.03 | 23.72 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.